L-054,522

    WARNING: This product is for research use only, not for human or veterinary use.

Hodoodo CAT#: H532049

CAS#: 214348-67-1

Description: L-054,522 is potent, selective somatostatin receptor agonists.

Chemical Structure

img
L-054,522
CAS# 214348-67-1
Instruction

Theoretical Analysis

Hodoodo Cat#: H532049
Name: L-054,522
CAS#: 214348-67-1
Chemical Formula: C35H47N7O5
Exact Mass: 645.36
Molecular Weight: 645.810
Elemental Analysis: C, 65.09; H, 7.34; N, 15.18; O, 12.39

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @hodoodo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Synonym: L-054,522; L 054,522; L054,522.

IUPAC/Chemical Name: tert-butyl (2S)-6-amino-2-[[(2R,3S)-3-(1H-indol-3-yl)-2-[[4-(2-oxo-3H-benzimidazol-1-yl)piperidine-1-carbonyl]amino]butanoyl]amino]hexanoate

InChi Key: WFCIXKAZBUIFTR-PKIMSIDOSA-N

InChi Code: InChI=1S/C35H47N7O5/c1-22(25-21-37-26-12-6-5-11-24(25)26)30(31(43)38-28(14-9-10-18-36)32(44)47-35(2,3)4)40-33(45)41-19-16-23(17-20-41)42-29-15-8-7-13-27(29)39-34(42)46/h5-8,11-13,15,21-23,28,30,37H,9-10,14,16-20,36H2,1-4H3,(H,38,43)(H,39,46)(H,40,45)/t22-,28-,30+/m0/s1

SMILES Code: O=C(OC(C)(C)C)[C@@H](NC([C@H](NC(N1CCC(N2C3=CC=CC=C3NC2=O)CC1)=O)[C@H](C4=CNC5=C4C=CC=C5)C)=O)CCCCN

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 645.81 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Stark A, Mentlein R. Somatostatin inhibits glucagon-like peptide-1-induced insulin secretion and proliferation of RINm5F insulinoma cells. Regul Pept. 2002 Oct 15;108(2-3):97-102. PubMed PMID: 12220732.

2: Mentlein R, Eichler O, Forstreuter F, Held-Feindt J. Somatostatin inhibits the production of vascular endothelial growth factor in human glioma cells. Int J Cancer. 2001 May 15;92(4):545-50. PubMed PMID: 11304689.

3: Held-Feindt J, Forstreuter F, Pufe T, Mentlein R. Influence of the somatostatin receptor sst2 on growth factor signal cascades in human glioma cells. Brain Res Mol Brain Res. 2001 Feb 19;87(1):12-21. PubMed PMID: 11223155.

4: Rohrer SP, Schaeffer JM. Identification and characterization of subtype selective somatostatin receptor agonists. J Physiol Paris. 2000 May-Aug;94(3-4):211-5. PubMed PMID: 11087999.

5: Pasternak A, Pan Y, Marino D, Sanderson PE, Mosley R, Rohrer SP, Birzin ET, Huskey SE, Jacks T, Schleim KD, Cheng K, Schaeffer JM, Patchett AA, Yang L. Potent, orally bioavailable somatostatin agonists: good absorption achieved by urea backbone cyclization. Bioorg Med Chem Lett. 1999 Feb 8;9(3):491-6. PubMed PMID: 10091708.

6: Yang L, Berk SC, Rohrer SP, Mosley RT, Guo L, Underwood DJ, Arison BH, Birzin ET, Hayes EC, Mitra SW, Parmar RM, Cheng K, Wu TJ, Butler BS, Foor F, Pasternak A, Pan Y, Silva M, Freidinger RM, Smith RG, Chapman K, Schaeffer JM, Patchett AA. Synthesis and biological activities of potent peptidomimetics selective for somatostatin receptor subtype 2. Proc Natl Acad Sci U S A. 1998 Sep 1;95(18):10836-41. PubMed PMID: 9724791; PubMed Central PMCID: PMC27982.